EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases

Eligibility criteria

Patients' inclusion criteria: • Group A: Patients with EBV driven lymphomas (e.g., NK/T-cell lymphoma), with EBV complications (e.g. HLH, CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g. SCID) with planned allogeneic HCT • Group B: EBV-driven PTLD that develop after a HCT or SOT For both groups: • All age groups • Negative pregnancy test in female patients of childbearing potential. • Signed written informed consent of patient or/and parents Patients' exclusion criteria: • Patients receiving anti-thymocyte globulin or Campath within 28 days of infusion • Patients with active, acute GvHD grades III-IV • Previous severe reaction to dimethylsulfoxide (DMSO) Donors' inclusion criteria: • EBV positive serology (VCA and Epstein-Barr nuclear antigen (EBNA) immunoglobulin G (IgG) positive) • Detectable interferon (IFN)-y-secreting T cells (\>100 SFC/10e6 PBMC) measured by Elispot to the EBV consensus peptide pool • Suitability for blood or HCT donation meeting requirements of local institutional guidelines • An informed consent for EBV Tscm CTL manufacturing • Age \> 18 years Donors' exclusion criteria: • Detectable IFN-y-secreting T-cells \<100 spot-forming cell (SFC)/10e6 PBMC measured by Elispot to EBV select • Unwilling and/or unable to donate, according to the donor center